Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Mesenbio logo — Using mesenchymal stem cells to produce therapeutically mean...

Mesenbio

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles.

Founded 2021 United Kingdom York, United Kingdom 9 employees Seed Total: $1.40M Biotechnology, Health and Wellness

General Information

Company Name Mesenbio
Founded Year 2021
Location United Kingdom York, United Kingdom +1
Employees 9
Industries Biotechnology, Health and Wellness
Funding Stage Seed
Social

Get notified when Mesenbio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Mesenbio

Mesenbio is a biotechnology startup founded in 2021 in the United Kingdom. The company's focus lies in utilizing mesenchymal stem cells (MSCs) to produce therapeutically meaningful extracellular vesicles (EVs). Mesenbio's innovation has garnered attention and secured a significant £1.40M investment in a Seed Round on 09 January 2024 from NG Bio and DSW Ventures. Spun out from the Genever lab with over 20 years of expertise in cell biology and regenerative medicine at the University of York, Mesenbio's approach addresses the limitations of current therapies by providing an endless source of therapeutically active EVs with improved batch consistency. Their focus on musculoskeletal regeneration, particularly targeting osteoarthritis, presents a compelling solution to a significant socioeconomic burden, considering the aging populations and the lack of disease-modifying drugs. The company's agile and versatile MSC-EV production platform positions them as a potential game-changer in the biotechnology space. With a promising technology and a strong investment backing, Mesenbio exhibits the potential to bring about significant advancements in the field of regenerative medicine and therapeutic EV production.

Taxonomy: Extracellular Vesicles, Exosomes, Mesenchymal Stem Cells, Regenerative Medicine, Therapeutics, Cell Biology, Musculoskeletal Regeneration, Osteoarthritis, Preclinical Biopharmaceutical, Platform Technologies, Cell Lines, Anti-inflammatory Effect, Cargo Delivery, Cutting Edge Therapeutics

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
09 Jan 2024
Seed Round •••••• 2
Investor
•••• •••• 		09 Jan 2024

Mesenbio Alternatives & Competitors

Mesenbio vs
advanceCor GmbH
advanceCor GmbH Germany

Biotech company independent development of innovative drugs + diagnostics for heart disease, cardiol...

Unknown
5 employees
Biotechnology
Mesenbio vs
Re-Vana Therapeutics
Re-Vana Therapeutics United Kingdom

To advance the quality of care for patients suffering from sight-threatening diseases.

Series A
23 employees
Health Care, Health and Wellness
Mesenbio vs
Likarda, Inc.
Likarda, Inc. United States

Transforming How Cell Therapies, Biologics, Peptides, and Hormones Are Delivered

Unknown
14 employees
Biotechnology, Health and Wellness

FAQ About Mesenbio

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles.
Mesenbio was founded in 2021.
Mesenbio is headquartered in York, United Kingdom.
Mesenbio operates in the following industries: Biotechnology, Health and Wellness.
Mesenbio has approximately 9 employees.
Mesenbio has completed 2 funding rounds, raising a total of $1.40M. The latest funding stage is Seed.
Top alternatives and competitors to Mesenbio include advanceCor GmbH, Re-Vana Therapeutics, Likarda, Inc., GeneMedicine, Xap Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mesenbio and advanceCor GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Mesenbio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy